If things go according to plan, more companion diagnostic developers will be able to market their tests to detect cancers that can be treated with a wider range of drugs and biologics. So far, such tests have typically been approved as companions to an individual treatment but a new draft guidance could change that by allowing them for therapeutic classes rather than specific treatments.
US FDA says the current standard for cancer drug/IVD pairings limit the kinds of treatments patients have access to and...